Wu Jheng-Yan, Hu Khai-Chi, Liu Mei-Yuan, Wu Yu-Jou, Hsu Wan-Hsuan, Tsai Ya-Wen, Liu Ting-Hui, Huang Po-Yu, Chuang Min-Hsiang, Yu Tsung, Liao Kuang-Ming, Lai Chih-Cheng
Department of Nutrition, Chi Mei Medical Center, Tainan, Taiwan.
Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Nat Commun. 2025 Jul 1;16(1):5478. doi: 10.1038/s41467-025-60582-y.
Diabetes is common in patients with chronic obstructive pulmonary disease. Sodium-glucose co-transporter-2 inhibitors are effective in treating type 2 diabetes and provide benefits for conditions like cardiovascular and kidney diseases. We use data from multiple institutions and countries to evaluate their role in patients with chronic obstructive pulmonary disease and diabetes. This study includes chronic obstructive pulmonary disease patients with diabetes who are newly prescribed sodium-glucose co-transporter-2 inhibitors or dipeptidyl peptidase-4 inhibitors between January 1, 2013, and August 25, 2024. The primary outcome is all-cause mortality. The results show that the sodium-glucose co-transporter-2 inhibitors group has a lower risk of all-cause mortality compared to the dipeptidyl peptidase-4 inhibitors group (hazard ratio, 0.757; 95% confidence interval, 0.716-0.801). It also shows significantly lower risks of all-cause hospitalization (hazard ratio, 0.864; 95% confidence interval, 0.845-0.884), exacerbation (hazard ratio, 0.924; 95% confidence interval, 0.888-0.962), pneumonia, upper respiratory infections, bronchitis, and major cardiovascular events.
糖尿病在慢性阻塞性肺疾病患者中很常见。钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病有效，并对心血管疾病和肾脏疾病等病症有益。我们使用来自多个机构和国家的数据来评估它们在慢性阻塞性肺疾病合并糖尿病患者中的作用。本研究纳入了在2013年1月1日至2024年8月25日期间新开具钠-葡萄糖协同转运蛋白2抑制剂或二肽基肽酶4抑制剂的慢性阻塞性肺疾病合并糖尿病患者。主要结局是全因死亡率。结果显示，与二肽基肽酶4抑制剂组相比，钠-葡萄糖协同转运蛋白2抑制剂组的全因死亡风险更低（风险比，0.757；95%置信区间，0.716 - 0.801）。它还显示出全因住院（风险比，0.864；95%置信区间，0.845 - 0.884）、病情加重（风险比，0.924；95%置信区间，0.888 - 0.962）、肺炎、上呼吸道感染、支气管炎和主要心血管事件的风险显著更低。
